Videos

The VISION Study in Metastatic CRPC

July 23rd 2021

An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

PSMA PET Imaging in Advanced Prostate Cancer

July 23rd 2021

A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.

PSMA as a Biomarker in Advanced Prostate Cancer

July 23rd 2021

Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.

Tebentafusp for Uveal Melanoma: Assessing Treatment Response

July 23rd 2021

Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.

Tebentafusp Efficacy Data in Uveal Melanoma

July 23rd 2021

Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies.

Steroid Refractory GVHD: Scope of the Problem

July 23rd 2021

Dr Chen provides an overview of the prevalence of steroid refractory GVHD and leads a discussion on how steroid refractory GVHD is defined.

Individualized Treatment for MDS

July 23rd 2021

The panel of leukemia experts highlight the importance of individualized treatments for patients with myelodysplastic syndrome.

Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer

July 23rd 2021

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

Management of Chronic GVHD

July 23rd 2021

Dr Cutler leads a discussion on the approach to management of chronic GVHD and whether complete response is a realistic end point.

Staging Models in Diagnosis and Risk Assessment of MDS

July 23rd 2021

Rami Komrokji, MD, and Gail Roboz, MD, discuss the importance of staging models in the diagnosis and routine assessment of patients with myelodysplastic syndrome.

Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC

July 23rd 2021

David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.

Tebentafusp for Uveal Melanoma

July 23rd 2021

Drs Richard D. Carvajal and Marlana M. Orloff comment on tebentafusp’s mechanism of action (MOA) and explain what makes the therapy attractive for uveal melanoma.

Uveal Melanoma: Current Treatment Approaches

July 23rd 2021

A brief explanation regarding the difference between uveal melanoma and skin melanoma and an overview of standard treatment approaches used to treat patients with uveal melanoma.

Dr. Rampal on Selecting Among Available JAK Inhibitors in Myelofibrosis

July 22nd 2021

Raajit K. Rampal, MD, PhD, discusses considerations for selecting among the JAK inhibitors ruxolitinib and fedratinib in the treatment of patients with myelofibrosis.

Dr. Carey on the ​Results of the monarchE Trial in HR+/HER2- Breast Cancer

July 22nd 2021

Lisa A. Carey, MD, FASCO, discusses the phase 3 monarchE trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Burnham on Closing the Gap in Health Disparities in Prostate Cancer

July 22nd 2021

Leanne Burnham, PhD, discusses the need to close the gap in health disparities in prostate cancer.

Dr. Thompson on Emerging Treatment Strategies With BTK Inhibitors in CLL

July 22nd 2021

Meghan Thompson, MD, discusses emerging treatment strategies with BTK inhibitors in chronic lymphocytic leukemia.

Dr. Basho on the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

July 22nd 2021

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Pecot on the Growth of Actionable Targets in Lung Cancer

July 22nd 2021

Chad V. Pecot, MD, discusses the growth of actionable targets in lung cancer.

Tumor-Normal Matched Sequencing and Platforms Utilized for Tumor Profiling

July 22nd 2021

Mark Robson, MD, reviews data from a recent abstract on incidental germline findings detected by tumor-normal matched sequencing and the panelists share which platforms they utilize for tumor profiling.

Defining Germline Sequencing and Incidental Germline Findings

July 22nd 2021

Mark Robson, MD, and a panel of experts discuss key terminology and definitions related to tumor and germline sequencing.

Molecular Testing Turnaround Time and Treatment Delay

July 22nd 2021

Key opinion leaders in acute myeloid leukemia reflect on challenges associated with molecular testing by commenting on potential treatment delay from the long turnaround time (TAT) of next-generation sequencing.

ASCO 2021: New Data for NSCLC Treatment Options

July 22nd 2021

Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).

Treatment Considerations: Chemotherapy + IO in ES SCLC

July 22nd 2021

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

Molecular Testing for Acute Myeloid Leukemia

July 22nd 2021

Mark Levis, MD, PhD, leads a panel of experts in a discussion on factors to consider when ordering molecular testing for newly diagnosed and relapsed/refractory acute myeloid leukemia.

NSCLC: EGFR Exon 20 Insertion Treatment Options

July 22nd 2021

Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .

First-Line Therapy in ES SCLS: KEYNOTE-604

July 22nd 2021

Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.

Dr. Cohen on the Preliminary Results of the GALAXY Study in CRC

July 21st 2021

Stacey A. Cohen MD, discusses the preliminary results of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

Dr. Gradishar on the Significance of Drug Development in HER2+ Breast Cancer

July 21st 2021

William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

July 21st 2021

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

NEXT PAGE
PREVIOUS PAGE